Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced and unlikely to make it to market for several years, industry experts say.
Civica, Inc., the nonprofit drug manufacturer contracted to produce insulin for California, has not started clinical trials or applied for approval from the federal Food and Drug Administration, both of which are likely to take more than a year to complete.
During his 2023 State of the State tour, Newsom announced California would begin selling insulin for $30 a vial with a “2024 delivery in terms of timeline,” pending FDA approval.
For more on this story, please visit ap.com.
